Abstrakt

Iron is an essential microelement in the human body due to its role in hematopoiesis, involvement in energetic processes, synthesis and decomposition of lipids, proteins and nuclear acids. Iron deficiency (ID) is common in healthy populations and also frequently coincides with natural course of chronic diseases. The former is typically present when the overall iron body storages are exhausted (absolute ID), most often due to insufficient iron supply, malabsorption or increased blood loss and coincides with anemia. The latter is a result of defected iron metabolism and reflects a condition, when despite adequate iron stores in the body, iron itself is trapped in the reticuloendothelial system, becoming unavailable for the metabolic processes. It typically occurs in the presence proinflammtory activation in chronic conditions such as chronic kidney disease, inflammatory bowel disorders, malignancies and heart failure. To date there are very few publications concerning the potential role of ID in chronic dermatological disorders. We have recently found that patients with psoriasis demonstrate pattern of ID which can be characterized by negative tissue iron balance with depleted iron stores in the body. Interestingly, presence of ID was not related to the severity of psoriasis, but rather determined by patients low body mass index. We are currently investigating the hypothesis that derangements in iron metabolism resulting in ID can be also present in hidradenitis suppurativa – the other chronic dermatologic disease associated with inflammatory and autoimmune activation.

Przypisy

• 1. Anderson G.J., Frazer D.M., McLaren G.D.: Iron absorption andmetabolism. Curr. Opin. Gastroenterol., 2009; 25: 129–35
  Google Scholar
• 2. Baliwag J., Barnes D.H., Johnston A.: Cytokines in psoriasis. Cytokine, 2015; 73: 342–50
  Google Scholar
• 3. Cairo G., Bernuzzi F., Recalcati S.: A precious metal: iron, an essentialnutrient for all cells. Genes Nutr., 2006; 1: 25–39
  Google Scholar
• 4. Camaschella C.: Iron deficiency: new insights into diagnosis and treatment.Hematology Am. Soc. Hematol. Educ. Program., 2015; 2015: 8–13
  Google Scholar
• 5. Dev S., Babitt J.L.: Overview of iron metabolism in health anddisease. Hemodial. Int., 2017; 21: S6–S20
  Google Scholar
• 6. Dilek N., Dilek A.R., Sahin K., Kaklıkkaya N., Saral Y.: Hepcidinexpression in psoriasis patients. Indian J. Dermatol., 2014; 59: 630
  Google Scholar
• 7. Dunn L.L., Suryo Rahmanto Y., Richardson D.R.: Iron uptake andmetabolism in the new millennium. Trends Cell Biol., 2007; 17: 93–100
  Google Scholar
• 8. Dutra F.F., Bozza M.T.: Heme on innate immunity and inflammation.Front. Pharmacol., 2014; 5: 115
  Google Scholar
• 9. Dziegala M., Josiak K., Kasztura M., Kobak K., von Haehling S., BanasiakW., Anker S.D., Ponikowski P., Jankowska E.: Iron deficiency asenergetic insult to skeletal muscle in chronic diseases. J. CachexiaSarcopenia Muscle, 2018; 9: 802–815
  Google Scholar
• 10. Ganz T.: Systemic iron homeostasis. Physiol. Rev., 2013; 934: 1721–41
  Google Scholar
• 11. Ganz T., Nemeth E.: Hepcidin and iron homeostasis. Biochim.Biophys. Acta, 2012; 1823: 1434–43
  Google Scholar
• 12. Gozzelino R., Arosio P.: Iron homeostasis in health and disease.Int. J. Mol. Sci., 2016; 17: E130
  Google Scholar
• 13. Gulliver W., Lynde C., Dutz J.P., Vender R.B., Yeung J., BourcierM., Dion P.L., Hong C.H., Searles G., Poulin Y.: Think beyond the skin: 2014 Canadian expert opinion paper on treating to target in plaquepsoriasis. J. Cutan. Med. Surg., 2015; 19: 22–27
  Google Scholar
• 14. Gulliver W., Zouboulis C.C., Prens E., Jemec G.B., Tzellos T.: Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitissuppurativa. Rev. Endocr. Metab Disord., 2016; 17: 343–51
  Google Scholar
• 15. Hentze M.W., Muckenthaler M.U., Galy B., Camaschella C.: Two totango: regulation of mammalian iron metabolism. Cell, 2010; 142: 24–38
  Google Scholar
• 16. Jankowska E.A., Kasztura M., Sokolski M., Bronisz M., NawrockaS., Oleśkowska-Florek W., Zymliński R., Biegus J., Siwołowski P.,Banasiak W., Anker S.D., Filippatos G., Cleland J.G., Ponikowski P.:Iron deficiency defined as depleted iron stores accompanied byunmet cellular iron requirements identifies patients at the highestrisk of death after an episode of acute heart failure. Eur. Heart J.,2014; 35: 2468–76
  Google Scholar
• 17. Jankowska E.A., Malyszko J., Ardehali H., Koc-Zorawska E., BanasiakW., von Haehling S., Macdougall I.C., Weiss G., McMurray J.J.,Anker S.D., Gheorghiade M., Ponikowski P.: Iron status in patientswith chronic heart failure. Eur. Heart J., 2013; 34: 827–34
  Google Scholar
• 18. Jankowska E.A., von Haehling S., Anker S.D., Macdougall I.C.,Ponikowski P.: Iron deficiency and heart failure: diagnostic dilemmasand therapeutic perspectives. Eur. Heart J., 2013; 34: 816–26
  Google Scholar
• 19. Kelly G., Prens E.P.: Inflammatory mechanisms in hidradenitissuppurativa. Dermatol. Clin., 2016; 34: 51–58
  Google Scholar
• 20. Kelly G., Sweeney C.M., Tobin A.M., Kirby B.: Hidradenitis suppurativa:the role of immune dysregulation. Int. J. Dermatol., 2014; 53: 1186–96
  Google Scholar
• 21. Lee R.A., Eisen D.B.: Treatment of hidradenitis suppurativa withbiologic medications. J. Am. Acad. Dermatol., 2015; 73: S82–S83
  Google Scholar
• 22. Lubrano E., Cantini F., Costanzo A., Girolomoni G., PrignanoF., Olivieri I., Scarpa R., Spadaro A., Atzeni F., Narcisi A., Ricceri F.,Sarzi-Puttini P.: Measuring psoriatic disease in clinical practice. Anexpert opinion position paper. Autoimmun. Rev., 2015; 14: 864–74
  Google Scholar
• 23. Matusiak L., Bieniek A., Szepietowski J.C.: Increased serum tumournecrosis factor-α in hidradenitis suppurativa patients: is therea basis for treatment with anti-tumour necrosis factor-α agents?Acta. Derm. Venereol., 2009; 89: 601–603
  Google Scholar
• 24. Molin L., Reizenstein P.: Hematological changes in psoriasis.Secondary anemia, XVIII. Acta. Derm. Venereol., 1974; 54: 465–69
  Google Scholar
• 25. Montaudie H., Seitz-Polski B., Cornille A., Benzaken S., LacourJ.P., Passeron T.: Interleukin 6 and high-sensitivity C-reactive proteinare potential predictive markers of response to infliximab inhidradenitis suppurativa. J. Am. Acad. Dermatol., 2017; 76: 156–58
  Google Scholar
• 26. Muñoz M., García-Erce J.A., Remacha A.F.: Disorders of ironmetabolism. Part 1: Molecular basis of iron homoeostasis. J. Clin.Pathol., 2011; 64: 281–86
  Google Scholar
• 27. Muñoz M., García-Erce J.A., Remacha A.F.: Disorders of ironmetabolism. Part II: Iron deficiency and iron overload. J. Clin. Pathol., 2011; 64: 287–96
  Google Scholar
• 28. Nairz M., Haschka D., Demetz E., Weiss G.: Iron at the interfaceof immunity and infection. Front. Pharmacol., 2014; 5: 152
  Google Scholar
• 29. Nemeth E., Ganz T.: The role of hepcidin in iron metabolism.Acta Haematol., 2009; 122: 78–86
  Google Scholar
• 30. Ponikowska M., Matusiak L., Kasztura M., Jankowska E.A., SzepietowskiJ.C.: Deranged iron status in patients with hidradenitissuppurativa. Exp. Dermatol., 2019; 28: 28
  Google Scholar
• 31. Ponikowska M., Tupikowska M., Kasztura M., Jankowska E.A.,Szepietowski J.C.: Deranged iron status in psoriasis: the impact of lowbody mass. J. Cachexia Sarcopenia Muscle, 2015; 6: 358–64
  Google Scholar
• 32. Prystowsky J.H., Orologa A., Taylor S.: Update on nutrition andpsoriasis. Int. J. Dermatol., 1993; 32: 582–86
  Google Scholar
• 33. Rashmi R., Yuti A.M., Basavaraj K.H.: Enhanced ferritin/ironratio in psoriasis. Indian J. Med. Res., 2012; 135: 662–65
  Google Scholar
• 34. Rishi G., Wallace D.F., Subramaniam V.N.: Hepcidin: regulationof the master iron regulator. Biosci. Rep., 2015; 35: e00192
  Google Scholar
• 35. Schmidt P.J.: Regulation of iron metabolism by hepcidin underconditions of inflammation. J. Biol. Chem., 2015; 290: 18975–83
  Google Scholar
• 36. van der Zee H.H., de Ruiter L., van den Broecke D.G., Dik W.A., LamanJ.D., Prens E.P.: Elevated levels of tumour necrosis factor (TNF)-α,interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationalefor targeting TNF-α and IL-1β. Br. J. Dermatol., 2011; 164: 1292–98
  Google Scholar
• 37. van Veldhuisen D.J., Anker S.D., Ponikowski P., Macdougall I.C.:Anemia and iron deficiency in heart failure: mechanisms and therapeuticapproaches. Nat. Rev. Cardiol., 2011; 8: 485–93
  Google Scholar
• 38. Xu H., Xiao X., He Y., Zhang X., Li C., Mao Q., Wu X., Wang B.:Increased serum interleukin-6 levels in patients with hidradenitissuppurativa. Postępy Dermatol. Alergol., 2017; 34: 82–84
  Google Scholar
• 39. Zhang A.S., Enns C.A.: Molecular mechanisms of normal ironhomeostasis. Hematology Am. Soc. Hematol. Educ. Program, 2009;2009: 207–14
  Google Scholar
• 40. Zouboulis C.C., Desai N., Emtestam L., Hunger R.E, Ioannides D.,Juhász I., Lapins J., Matusiak L., Prens E.P., Revuz J., Schneider-BurrusS., Szepietowski J.C., van der Zee H.H., Jemec G.B.: European S1 guidelinefor the treatment of hidradenitis suppurativa/acne inversa.J. Eur. Acad. Dermatol. Venerol., 2015; 29: 619–44
  Google Scholar

Pełna treść artykułu